- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02093143
Conditions of Diagnostic Panendoscopy of the Upper Airway Under Propofol Remifentanil General Anesthesia (ENDOTANIL)
Evaluation of the Impact of Adding Remifentanil to Propofol on the Conditions of the Diagnostic Panendoscopy of the Upper Airway Under General Anesthesia With Tubeless Spontaneous Ventilation.
The most important considerations for the general anesthesia in diagnostic panendoscopy of the upper airway is the maintenance of a patient's airway for optimal surgical exposure, adequate ventilation and sufficient depth of anesthesia. Tubeless anesthestic techniques with preserved spontaneous ventilation and total intravenous administration of anesthetic drugs are widely use. Due to its pharmacological profile, propofol anesthesia is often considered as the gold standard for the anesthesia in the diagnostic panendoscopy. Previous studies suggested that adding remifentanil to propofol could improve the conditions for laryngoscopy and tracheal intubation.
The aim of this study is to assess the impact of propofol remifentanil general anesthesia compared to propofol general anesthesia on the conditions of the diagnostic panendoscopy of the upper airway.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Besançon, France, 25000
- Centre hospitalier régional universitaire
-
Besançon, France, 25000
- CHRU Besançon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elective diagnostic panendoscopy of the upper airway
- Age > 18 and < 80 years old
- American Society of Anesthesiology (ASA) score equal to 1, 2, or 3 with a stable condition
- Written inform consent
Exclusion Criteria:
- Pregnancy or breastfeeding
- Age < 18 years old or inability to give informed consent
- Known anaphylaxis to remifentanil or propofol
- Long term opioid use, drug abuse
- Predictive criterion of impossible mask ventilation or intubation
- Chronic respiratory failure requiring oxygen therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remifentanil
The general anesthesia during the diagnostic panendoscopy of the upper airway will associate the target controlled infusion of propofol (pharmacologic model of Schnider et al.) and of remifentanil (pharmacologic model of Minto et al.) in the remifentanil group. The arm will be randomized prior to the beginning of the surgical procedure and blinded to the investigator and to the practitioner in charge of the patient. Two milligrams of remifentanil will be diluted in 40 cc of sodium chloride 0,9% in a 50 ml syringe. |
Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
Other Names:
|
Placebo Comparator: Placebo
The general anesthesia during the diagnostic panendoscopy of the upper airway will consist in the target controlled infusion of propofol alone (pharmacologic model of Schnider et al.) in the placebo group. The placebo is a 40 ml sodium chloride 0,9% solution in a 50 ml syringe. No one can distinguish the syringe of placebo from the syringe of remifentanil. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients presenting clinically acceptable conditions for the diagnostic panendoscopy of the upper airway
Time Frame: During the diagnostic panendoscopy of the upper airway
|
The assessment of the conditions for the diagnotic panendoscopy of the upper airway will be based on: (1) the conditions for the laryngoscopy ("excellent"=easy; "good"=fair; "poor"=difficult), (2) the position of the vocal cords ("excellent"=abducted; "good"=intermediate; "poor"=closed), (3) the movements of the vocal cords ("excellent"=none; "good"=moving; "poor"=closing), (4) the movement of the limbs ("excellent"=none; "good"=sight; "poor"=vigorous), (5) the cough ("excellent"=none; "good"=diaphragm; "poor"=sustained (>10 s)).
The conditions for the diagnostic panendoscopy will be considered as "excellent" when all variables will be excellent, as "good" when all variables will be either good or excellent and as "poor" when one or more variables will be graded as poor.
Clinically acceptable conditions are defined as either good or excellent conditions.
|
During the diagnostic panendoscopy of the upper airway
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DeltaHRmax
Time Frame: During the diagnostic panendoscopy
|
The DeltaHRmax characterises the amplitude of the maximal increase of the heart rate during the diagnostic panendoscopy of the upper airway.
The DeltaHRmax is defined as following: deltaHRmax=((HRmax-HRt0)*100)/HRt0).
HRmax is the highest value of the heart rate observed during the panendoscopy and HRt0 is the basal value of the heart rate.
|
During the diagnostic panendoscopy
|
DeltaHRmin
Time Frame: During the diagnostic panendoscopy
|
The DeltaHRmin characterises the amplitude of the maximal decrease of the heart rate during the diagnostic panendoscopy of the upper airway.
The DeltaHRmin is defined as following: deltaHRmin=((HRt0-HRmin)*100)/HRt0).
HRmin is the lowest value of the heart rate observed during the panendoscopy and HRt0 is the basal value of the heart rate.
|
During the diagnostic panendoscopy
|
DeltaMAPmin
Time Frame: During the diagnostic panendoscopy
|
The DeltaMAPmin characterises the amplitude of the maximal decrease of the heart rate during the diagnostic panendoscopy of the upper airway.
The DeltaHRmin is defined as following: deltaHRmin=((HRt0-HRmin)*100)/HRt0).
HRmin is the lowest value of the heart rate observed during the panendoscopy and HRt0 is the basal value of the heart rate.
|
During the diagnostic panendoscopy
|
DeltaMAPmax
Time Frame: During the diagnostic pandoscopy
|
The DeltaMAPmax characterises the amplitude of the maximal increase of the mean arterial pressure (MAP) during the diagnostic panendoscopy of the upper airway.
The DeltaMAPmax is defined as following: deltaMAPmax=((MAPmax-MAPt0)*100)/MAPt0).
MAPmax is the highest value of the mean arterial pressure (MAP) observed during the panendoscopy and MAPt0 is the basal value of the mean arterial pressure (MAP).
|
During the diagnostic pandoscopy
|
Proportion of patients presenting at least one episode of moderate hypoxemia
Time Frame: During the diagnostic panendoscopy
|
Moderate hypoxemia is defined as a pulse oximetry value (SpO2) under 94% during the diagnostic panendoscopy of the upper airway.
|
During the diagnostic panendoscopy
|
Proportion of patients presenting at least one episode of severe hypoxemia
Time Frame: During the diagnostic panendoscopy
|
Severe hypoxemia is defined as a pulse oximetry value (SpO2) under 90% during the diagnostic panendoscopy of the upper airway.
|
During the diagnostic panendoscopy
|
Proportion of patients requiring invasive mechanical ventilation
Time Frame: During the diagnostic panendoscopy
|
Invasive mechanical ventilation via an emergent surgical tracheotomy or an endotracheal intubation could be required in case of life-threatened hypoxemia during the diagnostic panendoscopy of the upper airway.
|
During the diagnostic panendoscopy
|
Proportion of patients presenting surgery complications
Time Frame: During the panendoscopy of the upper airway
|
Surgical complications are defined as dental breakage, bleeding or mucosal injuries directly related to the diagnostic panendoscopy of the upper airway or to the biopsy.
|
During the panendoscopy of the upper airway
|
Collaborators and Investigators
Investigators
- Principal Investigator: Guillaume Besch, MD, CHRU Besançon
- Principal Investigator: Sébastien Pili Floury, MD, PhD, CHRU Besançon
- Principal Investigator: Angéline Chopard-Guillemin, MD, CHRU Besançon
- Principal Investigator: Amélie Jurine, MD, CHRU Besançon
- Principal Investigator: Arnaud Causeret, MD, CHRU Besançon
Publications and helpful links
General Publications
- Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, Shafer SL. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997 Jan;86(1):10-23. doi: 10.1097/00000542-199701000-00004.
- Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, Youngs EJ. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology. 1998 May;88(5):1170-82. doi: 10.1097/00000542-199805000-00006.
- Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997 Jan;86(1):24-33. doi: 10.1097/00000542-199701000-00005.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Otorhinolaryngologic Diseases
- Ear Diseases
- Ear Neoplasms
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Remifentanil
Other Study ID Numbers
- P/2008/78
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor of Ear, Nose and Throat
-
Mansoura UniversityCompletedMalignant Tumor of the LarynxEgypt
-
Mansoura UniversityCompleted
-
UNC Lineberger Comprehensive Cancer CenterUNC Translational and Clinical Sciences (Tracs)CompletedA History of Radiation Therapy for a Tumor in the Vicinity of the Retina(s)United States
-
First Affiliated Hospital of Fujian Medical UniversityCompletedTumor Positron-Emission TomographyChina
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityCompletedAcute Toxic Effects | Tumor ResponsesChina
-
PRECLIN Biosystems AGCompletedUnspecified Disorder of Nose and Nasal SinusesSwitzerland
-
Yonsei UniversityCompletedEar,Nose and Throat SurgeryKorea, Republic of
-
Sensoptic SACompletedOtosclerosis of Middle Ear | Cholesteatoma, Middle Ear | Disorder of Middle Ear
-
State University of New York at BuffaloCompletedPercent of Glottic Opening
-
University of British ColumbiaCompleted
Clinical Trials on Remifentanil
-
University Medical Center GroningenCompletedAnesthesia | Hemodynamic Instability | Interaction | Disorder of Oxygen TransportNetherlands
-
Inje UniversityCompletedStrabismusKorea, Republic of
-
Ciusss de L'Est de l'Île de MontréalCompletedIntubation; Difficult or FailedCanada
-
Helse FonnaCompletedAnesthesia, General | Anesthesia, Intravenous | Hemodynamic InstabilityNorway
-
Hopital FochCompletedGeneral AnesthesiaFrance
-
Zhang HaopengCompleted
-
Capital Medical UniversityRecruitingCerebral Blood Flow | Hyperventilation | Aneurysmal Subarachnoid HemorrhageChina
-
University of AarhusMech-SenseCompleted
-
Seoul National University HospitalAjou University School of Medicine; Severance HospitalCompletedInfant, PretermKorea, Republic of
-
University Hospital, GhentCompleted